Ireland
--:--IST
Latest
Airmid Éireann 1.4 Puts Irish Pharma Data in Global Context Northern Ireland Phone Switch-Off: Check Medical Devices Irish Medtech Calls for MDR and IVDR Reform at Galway Event Clonmel Healthcare Launches Mabelle Menocare Supplements HealthSpan Partners to Acquire Irish GP Group Centric Health Outpatient Waiting List Reaches 692,524, Up 10.5% in a Year Airmid Éireann 1.4 Puts Irish Pharma Data in Global Context Northern Ireland Phone Switch-Off: Check Medical Devices Irish Medtech Calls for MDR and IVDR Reform at Galway Event Clonmel Healthcare Launches Mabelle Menocare Supplements HealthSpan Partners to Acquire Irish GP Group Centric Health Outpatient Waiting List Reaches 692,524, Up 10.5% in a Year
Clinical Trials in Canada / NCT07624071
Recruiting Phase 1

A Study to Evaluate ALN-6222 in Participants With Obesity

NCT07624071 · tracked via the Priya Life Science Canada tracker
Sponsor
Alnylam Pharmaceuticals
Phase
Phase 1
Started
2026-06-04
Last updated
2026-10-21

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

ALN-6222Placebo

ALN-6222: ALN-6222 will be administered subcutaneously (SC).

Placebo: Placebo will be administered SC.

Study summary

This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria - * Is an adult patient with a body mass index ≥30 kg/m\^2 to \<40 kg/m\^2 * Has a hemoglobin A1c \<6.5% Exclusion Criteria - * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>1.5 times the upper limit of normal (ULN) * Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection * Has an estimated glomerular filtration (eGFR) of \<60 mL/min/1.73m\^2 at screening Note: other protocol defined inclusion / exclusion criteria apply

Primary outcome measure(s)

  • Frequency of Adverse Events — Up to 12 months

Trial sites (1)

FacilityCityRegionStatus
Clinical Trial Site Mount Royal Canada Recruiting

More Alnylam Pharmaceuticals trials in Canada

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Active, not recruiting
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Active, not recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy Recruiting
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD Recruiting

Other trials for the same condition

Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control Recruiting
Obesity Medicine Bank of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) Starting soon
Impact of Milk and Yogurt Supplementation on Bone Health, Body Composition, and Gut Microbiota in Canadian Young Adults Recruiting
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight Active, not recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07624071 on ClinicalTrials.gov ↗ ← All trials in Canada